| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/02/2004 | US20040170603 Using radiolabeled annexin; radiotherapy for tumors |
| 09/02/2004 | DE10307165A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and processes for their preparation |
| 09/02/2004 | CA2787820A1 Glycoprotein antigen sima135 expressed in metastatic human tumor cells |
| 09/02/2004 | CA2518311A1 Superoxide anion scavenger |
| 09/02/2004 | CA2516701A1 Modulation of the poliovirus receptor function |
| 09/02/2004 | CA2516685A1 Peptidomimetic inhibitors of stat3 activity and their medical uses |
| 09/02/2004 | CA2516453A1 Composition and methods for inhibiting cell survival |
| 09/02/2004 | CA2516426A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 09/02/2004 | CA2516335A1 A method of diagnosis and treatment |
| 09/02/2004 | CA2516234A1 N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| 09/02/2004 | CA2516184A1 Antitumoral d-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates |
| 09/02/2004 | CA2516177A1 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action |
| 09/02/2004 | CA2515887A1 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier |
| 09/02/2004 | CA2515610A1 Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use |
| 09/02/2004 | CA2515480A1 Use of acylated aminopropanediols and sulphur and nitrogen analogues of same for different therapeutic applications |
| 09/02/2004 | CA2514862A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/02/2004 | CA2514485A1 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components |
| 09/02/2004 | CA2514277A1 Methods and compositions for administering therapeutic and diagnostic agents |
| 09/01/2004 | EP1452545A1 Novel chitosans |
| 09/01/2004 | EP1452527A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation |
| 09/01/2004 | EP1452522A2 Novel compounds and compositions as protease inhibitors |
| 09/01/2004 | EP1452521A1 Cyclic compound and ppar agonist |
| 09/01/2004 | EP1452181A1 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/01/2004 | EP1452178A1 Persistent filmy preparation for topical administration containing prostaglandin derivative |
| 09/01/2004 | EP1451578A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 09/01/2004 | EP1451333A2 Ul16 binding protein 4 |
| 09/01/2004 | EP1451322A2 Il-21 antagonists |
| 09/01/2004 | EP1451308A2 Therapeutic use of aziridino compounds |
| 09/01/2004 | EP1451305A2 Epitope synchronization in antigen presenting cells |
| 09/01/2004 | EP1451303A1 Detection of haematopoietic stem cells and progeny and uses thereof |
| 09/01/2004 | EP1451226A1 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| 09/01/2004 | EP1451222A2 Novel proteins with il-6 inhibiting activity |
| 09/01/2004 | EP1451221A2 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN |
| 09/01/2004 | EP1451219A1 Nuclear protein "shoca" - a component of the wnt signalling pathway |
| 09/01/2004 | EP1451218A2 Methods for the treatment and prognosis of leukemia and other cancer types |
| 09/01/2004 | EP1451212A2 Structural and cytoskeleton-associated proteins |
| 09/01/2004 | EP1451210A2 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451209A2 Tetra-,penta-,hexa- and heptapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451193A1 Podophyllotoxins as antiproliferative agents |
| 09/01/2004 | EP1451192A1 Novel crystalline compound |
| 09/01/2004 | EP1451191A1 Thioether substituted imidazoquinolines |
| 09/01/2004 | EP1451190A1 Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof |
| 09/01/2004 | EP1451187A1 Amide substituted imidazopyridines |
| 09/01/2004 | EP1451186A2 Urea substituted imidazopyridines |
| 09/01/2004 | EP1451168A2 Paclitaxel solvates |
| 09/01/2004 | EP1451166A1 Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof |
| 09/01/2004 | EP1451165A1 Substituted benzoxazoles and analogues as estrogenic agents |
| 09/01/2004 | EP1451156A1 4-aminoquinoline compounds |
| 09/01/2004 | EP1450862A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 09/01/2004 | EP1450856A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 09/01/2004 | EP1450850A1 Method of administering a thymosin alpha 1 peptide |
| 09/01/2004 | EP1450847A2 Apo2 ligand/trail formulations |
| 09/01/2004 | EP1450844A2 Polymeric thiol-linked prodrugs employing benzyl elimination systems |
| 09/01/2004 | EP1450842A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 09/01/2004 | EP1450841A2 Tri-, tetra-, and penta-peptides having antiangiogenic activity |
| 09/01/2004 | EP1450840A2 Di-, tri,- and tetra-peptides having antiangiogenic activity |
| 09/01/2004 | EP1450839A2 Method of treating estrogen responsive breast cancer |
| 09/01/2004 | EP1450836A2 Method for short-term and long-term drug dosimetry |
| 09/01/2004 | EP1450832A2 Lactic acid bacteria and their use for treating and preventing cancer |
| 09/01/2004 | EP1450830A2 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors |
| 09/01/2004 | EP1450828A2 In situ immunization |
| 09/01/2004 | EP1450822A2 Polymeric thiol-linked prodrugs |
| 09/01/2004 | EP1450821A1 Immunostimulatory oligodeoxynucleotides |
| 09/01/2004 | EP1450820A2 Method for treating or preventing inflammatory diseases |
| 09/01/2004 | EP1450814A2 Methods of inhibiting metastases |
| 09/01/2004 | EP1450812A2 Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| 09/01/2004 | EP1450801A2 2-aminoquinoline compounds |
| 09/01/2004 | EP1450799A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 09/01/2004 | EP1450791A1 Hydrazonopyrazole derivatives and their use as therapeutics |
| 09/01/2004 | EP1450781A1 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 09/01/2004 | EP1450777A1 Pharmaceutical composition containing chalcone or its derivatives for matrix metalloproteinase inhibitory activity |
| 09/01/2004 | EP1450769A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 09/01/2004 | EP1450750A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase |
| 09/01/2004 | EP1347984B1 A process for the preparation of taxan derivatives |
| 09/01/2004 | EP1292594B1 Quinazoline derivatives for the treatment of tumours |
| 09/01/2004 | EP1242410B1 Novel compounds |
| 09/01/2004 | EP1228024B1 Novel hydronaphthalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 09/01/2004 | EP1127058B1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 09/01/2004 | EP1123008A4 Preparation and use of solidified oils |
| 09/01/2004 | EP1089764B1 Stimulating the immune system |
| 09/01/2004 | EP1037529A4 Composition useful for providing one-step surgical preparation and drape |
| 09/01/2004 | EP0984955B1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing tnf alpha levels |
| 09/01/2004 | EP0975764B1 A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin |
| 09/01/2004 | EP0923530B1 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
| 09/01/2004 | CN1526025A Genes expressed in breast cancer as prognostic and therapeutic targets |
| 09/01/2004 | CN1526020A Di- or oligomer of a dimer, trimer, quatrometer or pentamer of recombinant fusion proteins. |
| 09/01/2004 | CN1526012A A specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it |
| 09/01/2004 | CN1525967A N-苯基-2-嘧啶胺衍生物 N- phenyl-2-pyrimidine-amine derivatives |
| 09/01/2004 | CN1525956A Alpha -amino-n-hydroxy-acetamide derivatives |
| 09/01/2004 | CN1525955A Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 09/01/2004 | CN1525954A Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 09/01/2004 | CN1525868A Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 09/01/2004 | CN1525866A Treatment using neublastin polypeptides |
| 09/01/2004 | CN1525865A Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 09/01/2004 | CN1525864A Mucin peptide with immunoenhancing properties |
| 09/01/2004 | CN1525862A Novel receptors for dollar i(helicobacter pylori) and use thereof |
| 09/01/2004 | CN1525859A Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| 09/01/2004 | CN1525857A Method for regulation of gene expression in eukaryotic cells using nordihydroguaiaretic acid derivatives |
| 09/01/2004 | CN1524952A False virosome vaccine with recombinant replicon of dengue fever virus as carrier |
| 09/01/2004 | CN1524951A Vaccine for human papiloma virus |